ArticleJournal of cosmetic dermatology2026
Real-World Use of Polynucleotide Injections in Scar Prevention and Management: A Nationwide Survey of Korean Society for Anti-Aging Dermatology (KAAD) Dermatologists.
Article in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundScarring is a common dermatologic concern with both aesthetic and functional implications. Polynucleotide (PN)-based injectables have emerged as medical devices in dermatologic practice; however, real-world evidence on their use in scar management remains limited.
objectiveTo describe current clinical practices, application patterns, and perceived roles of PN injections in scar prevention and management among dermatologists belonging to the Korean Society for Anti-Aging Dermatology (KAAD).
methodsA nationwide, cross-sectional, web-based survey was conducted among KAAD dermatologists. The questionnaire assessed PN use by scar type and etiology, injection techniques, combination strategies, and barriers to adoption. Data were analyzed descriptively.
resultsAmong 501 respondents, 73.0% reported using PN for scar management. PN was most commonly used for scar prevention (81.4%) and atrophic scars (74.9%), with limited use in hypertrophic scars (10.1%). Intradermal injection over three sessions was the most common approach. PN was frequently incorporated into multimodal protocols, including botulinum toxin, fillers, corticosteroids, bleomycin, and energy-based devices. Reported benefits included improved tissue response, enhanced skin texture, and accelerated wound recovery. Key barriers to PN adoption were product cost (66.7%), limited awareness of its role in scar management (52.6%), and injection discomfort (25.2%).
conclusionPN injections are commonly incorporated into scar prevention and management among KAAD dermatologists participating in this survey, particularly for acne-related, surgical, and traumatic scars. These findings provide real-world insight into current practice patterns and are hypothesis-generating. Prospective studies are needed to define optimal treatment protocols, including dosing, treatment intervals, and combination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.